Try our beta test site

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by Valeant Pharmaceuticals International, Inc.
Sponsor:
Information provided by (Responsible Party):
Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier:
NCT01846663
First received: April 24, 2013
Last updated: December 21, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2017
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)